Organelle-targeted Therapies: a Comprehensive Review on System Design for Enabling Precision Oncology

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2022 Nov 19

PMID 36402753

Authors

Jingjing Yang

Anthony Griffin

Zhe Qiang

Jie Ren

Affiliations

Soon will be listed here.

Abstract

Cancer is a major threat to human health. Among various treatment methods, precision therapy has received significant attention since the inception, due to its ability to efficiently inhibit tumor growth, while curtailing common shortcomings from conventional cancer treatment, leading towards enhanced survival rates. Particularly, organelle-targeted strategies enable precise accumulation of therapeutic agents in organelles, locally triggering organelle-mediated cell death signals which can greatly reduce the therapeutic threshold dosage and minimize side-effects. In this review, we comprehensively discuss history and recent advances in targeted therapies on organelles, specifically including nucleus, mitochondria, lysosomes and endoplasmic reticulum, while focusing on organelle structures, organelle-mediated cell death signal pathways, and design guidelines of organelle-targeted nanomedicines based on intervention mechanisms. Furthermore, a perspective on future research and clinical opportunities and potential challenges in precision oncology is presented. Through demonstrating recent developments in organelle-targeted therapies, we believe this article can further stimulate broader interests in multidisciplinary research and technology development for enabling advanced organelle-targeted nanomedicines and their corresponding clinic translations.

Citing Articles

Biomimetic Atorvastatin Self-Assembled Nanomedicine Inhibits the Cyclooxygenase-2/Prostaglandin E2 Pathway Enhanced Photothermal and Antitumor Immunity.

Zhou M, Han R, Xu W, Hao X, Peng Y, Tang Y Biomater Res. 2025; 29:0149.

PMID: 40040956 PMC: 11876541. DOI: 10.34133/bmr.0149.

Rejuvenation of Bone Marrow Mesenchymal Stem Cells: Mechanisms and Their Application in Senile Osteoporosis Treatment.

Tian R, Zhang R, Ma C Biomolecules. 2025; 15(2).

PMID: 40001580 PMC: 11853522. DOI: 10.3390/biom15020276.

Acid-Unlocked Two-Layer Ca-Loaded Nanoplatform to Interfere With Mitochondria for Synergistic Tumor Therapy.

Zheng Y, Williams G, Hu R, Tong S, Xu J, Wang T Int J Nanomedicine. 2025; 20:1899-1920.

PMID: 39963419 PMC: 11830942. DOI: 10.2147/IJN.S503248.

Hierarchical Targeting Nanodrug with Holistic DNA Protection for Effective Treatment of Acute Kidney Injury.

Chen Q, Yang Y, Ying X, Huang C, Chen J, Wang J Adv Sci (Weinh). 2024; 12(6):e2411254.

PMID: 39703158 PMC: 11809360. DOI: 10.1002/advs.202411254.

In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux.

Lv Y, Song B, Yang G, Wang Y, Wu Z, Si M Adv Sci (Weinh). 2024; 12(5):e2409425.

PMID: 39651805 PMC: 11791963. DOI: 10.1002/advs.202409425.

References

Fais S, De Milito A, You H, Qin W . Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007; 67(22):10627-30. DOI: 10.1158/0008-5472.CAN-07-1805. View

Braulke T, Bonifacino J . Sorting of lysosomal proteins. Biochim Biophys Acta. 2008; 1793(4):605-14. DOI: 10.1016/j.bbamcr.2008.10.016. View

Richter C . Do mitochondrial DNA fragments promote cancer and aging?. FEBS Lett. 1988; 241(1-2):1-5. DOI: 10.1016/0014-5793(88)81018-4. View

Bedi M, Ray M, Ghosh A . Active mitochondrial respiration in cancer: a target for the drug. Mol Cell Biochem. 2021; 477(2):345-361. DOI: 10.1007/s11010-021-04281-4. View

Kaina B . DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol. 2003; 66(8):1547-54. DOI: 10.1016/s0006-2952(03)00510-0. View

Paramore A, Frantz S . Bortezomib. Nat Rev Drug Discov. 2003; 2(8):611-2. DOI: 10.1038/nrd1159. View

Ozcan U, Cao Q, Yilmaz E, Lee A, Iwakoshi N, Ozdelen E . Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306(5695):457-61. DOI: 10.1126/science.1103160. View

Sang W, Zhang Z, Dai Y, Chen X . Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev. 2019; 48(14):3771-3810. DOI: 10.1039/c8cs00896e. View

Tkachenko A, Xie H, Liu Y, Coleman D, Ryan J, Glomm W . Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem. 2004; 15(3):482-90. DOI: 10.1021/bc034189q. View

10.

Soniat M, Chook Y . Nuclear localization signals for four distinct karyopherin-β nuclear import systems. Biochem J. 2015; 468(3):353-62. DOI: 10.1042/BJ20150368. View

11.

Dickmanns A, Kehlenbach R, Fahrenkrog B . Nuclear Pore Complexes and Nucleocytoplasmic Transport: From Structure to Function to Disease. Int Rev Cell Mol Biol. 2015; 320:171-233. DOI: 10.1016/bs.ircmb.2015.07.010. View

12.

Dielschneider R, Eisenstat H, Mi S, Curtis J, Xiao W, Johnston J . Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism. Leukemia. 2016; 30(6):1290-300. DOI: 10.1038/leu.2016.4. View

13.

Luo X, Gong X, Su L, Lin H, Yang Z, Yan X . Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. Angew Chem Int Ed Engl. 2020; 60(3):1403-1410. DOI: 10.1002/anie.202012237. View

14.

Rossi F, Campbell D, Pottier R, Kennedy J, Dickson E . In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. Br J Cancer. 1996; 74(6):881-7. PMC: 2074755. DOI: 10.1038/bjc.1996.452. View

15.

Chen W, Luo G, Zhang X . Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials. Adv Mater. 2018; 31(3):e1802725. DOI: 10.1002/adma.201802725. View

16.

Galluzzi L, Giordanetto F, Kroemer G . Targeting HSP70 for cancer therapy. Mol Cell. 2009; 36(2):176-7. DOI: 10.1016/j.molcel.2009.10.003. View

17.

Garg A, Maes H, van Vliet A, Agostinis P . Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol. 2016; 2(1):e975089. PMC: 4905250. DOI: 10.4161/23723556.2014.975089. View

18.

Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S . Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett. 2008; 18(20):5594-7. DOI: 10.1016/j.bmcl.2008.08.100. View

19.

Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bottzauw T, Nielsen C . Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008; 68(16):6623-33. DOI: 10.1158/0008-5472.CAN-08-0463. View

20.

Burdakov D, Petersen O, Verkhratsky A . Intraluminal calcium as a primary regulator of endoplasmic reticulum function. Cell Calcium. 2005; 38(3-4):303-10. DOI: 10.1016/j.ceca.2005.06.010. View